ArticleJournal of pharmacokinetics and pharmacodynamics2009
Pharmacogenetics and population pharmacokinetics: impact of the design on three tests using the SAEM algorithm.
Article in Journal of pharmacokinetics and pharmacodynamics, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Influence of body weight, ethnicity, oral contraceptives, and pregnancy on the pharmacokinetics of azithromycin in women of childbearing age.Antimicrobial agents and chemotherapy · 2012Trial
- Population pharmacokinetic-pharmacogenetic study of nevirapine in HIV-infected Cambodian patients.Antimicrobial agents and chemotherapy · 2010Trial
- Uncertainty Computation at Finite Distance in Nonlinear Mixed Effects Models-a New Method Based on Metropolis-Hastings Algorithm.The AAPS journal · 2024Article
- "De-Shrinking" EBEs: The Solution for Bayesian Therapeutic Drug Monitoring.Clinical pharmacokinetics · 2022Article
- Combined Analysis of Phase I and Phase II Data to Enhance the Power of Pharmacogenetic Tests.CPT: pharmacometrics & systems pharmacology · 2016Article
- Evaluation of Approaches to Deal with Low-Frequency Nuisance Covariates in Population Pharmacokinetic Analyses.The AAPS journal · 2015Article
- Comparison of Nonlinear Mixed Effects Models and Noncompartmental Approaches in Detecting Pharmacogenetic Covariates.The AAPS journal · 2015Article
- Statistical power calculations for mixed pharmacokinetic study designs using a population approach.The AAPS journal · 2014Article
- Powers of the likelihood ratio test and the correlation test using empirical bayes estimates for various shrinkages in population pharmacokinetics.CPT: pharmacometrics & systems pharmacology · 2014Article
- Effect of CYP3A4*22, CYP3A5*3, and CYP3A Combined Genotypes on Cyclosporine, Everolimus, and Tacrolimus Pharmacokinetics in Renal Transplantation.CPT: pharmacometrics & systems pharmacology · 2014Article
- Clinical trial simulation to evaluate power to compare the antiviral effectiveness of two hepatitis C protease inhibitors using nonlinear mixed effect models: a viral kinetic approach.BMC medical research methodology · 2013Article
- Cross-validation for nonlinear mixed effects models.Journal of pharmacokinetics and pharmacodynamics · 2013Article
- Shrinkage in nonlinear mixed-effects population models: quantification, influencing factors, and impact.The AAPS journal · 2012Article
- Population pharmacokinetics and pharmacogenetics of everolimus in renal transplant patients.Clinical pharmacokinetics · 2012Article
- Covariate pharmacokinetic model building in oncology and its potential clinical relevance.The AAPS journal · 2012Review
- Design of pharmacokinetic studies for latent covariates.Journal of pharmacokinetics and pharmacodynamics · 2012Article
- Development of a complex parent-metabolite joint population pharmacokinetic model.The AAPS journal · 2011Article
- Explaining variability in ciclosporin exposure in adult kidney transplant recipients.European journal of clinical pharmacology · 2010Article
- Bioequivalence tests based on individual estimates using non-compartmental or model-based analyses: evaluation of estimates of sample means and type I error for different designs.Pharmaceutical research · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pharmacogenetics is now widely investigated and health institutions acknowledge its place in clinical pharmacokinetics. Our objective is to assess through a simulation study, the impact of design on the statistical performances of three different tests used for analysis of pharmacogenetic information with nonlinear mixed effects models: (i) an ANOVA to test the relationship between the empirical Bayes estimates of the model parameter of interest and the genetic covariate, (ii) a global Wald test to assess whether estimates for the gene effect are significant, and (iii) a likelihood ratio test (LRT) between the model with and without the genetic covariate. We use the stochastic EM algorithm (SAEM) implemented in MONOLIX 2.1 software. The simulation setting is inspired from a real pharmacokinetic study. We investigate four designs with N the number of subjects and n the number of samples per subject: (i) N = 40/n = 4, similar to the original study, (ii) N = 80/n = 2 sorted in 4 groups, a design optimized using the PFIM software, (iii) a combined design, N = 20/n = 4 plus N = 80 with only a trough concentration and (iv) N = 200/n = 4, to approach asymptotic conditions. We find that the ANOVA has a correct type I error estimate regardless of design, however the sparser design was optimized. The type I error of the Wald test and LRT are moderatly inflated in the designs far from the asymptotic (<10%). For each design, the corrected power is analogous for the three tests. Among the three designs with a total of 160 observations, the design N = 80/n = 2 optimized with PFIM provides both the lowest standard error on the effect coefficients and the best power for the Wald test and the LRT while a high shrinkage decreases the power of the ANOVA. In conclusion, a correction method should be used for model-based tests in pharmacogenetic studies with reduced sample size and/or sparse sampling and, for the same amount of samples, some designs have better power than others.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.